FDA approves Welireg plus Lenvima for advanced clear-cell renal cell carcinoma after immunotherapy
The FDA has approved Welireg in combination with Lenvima for adults with advanced clear-cell renal cell carcinoma following prior PD-1 or PD-L1 immunotherapy.
The combination of belzutifan and lenvatinib achieved median progression-free survival of 14.6 months in the Phase III LITESPARK-011 study, compared with 10.6 months for cabozantinib.
The approval adds a new post-immunotherapy treatment option for patients with advanced kidney cancer and combines HIF-2α inhibition with VEGF-targeted therapy.
Field | Content |
Alert Type | Approval |
Drug Names | Belzutifan; lenvatinib |
Brand Names | Welireg; Lenvima |
Companies | Merck; Eisai |
Regulatory Authority | U.S. Food and Drug Administration |
Approval Type | Combination therapy approval |
Indication | Adults with advanced renal cell carcinoma with a clear-cell component following prior PD-1 or PD-L1 therapy |
Therapy Area(s) | Oncology; kidney cancer; renal cell carcinoma |
Technology or Modality | HIF-2α inhibitor plus multikinase inhibitor |
Clinical Study | LITESPARK-011 |
Median Progression-Free Survival | 14.6 months with belzutifan plus lenvatinib versus 10.6 months with cabozantinib |
Geography | United States |
What Happened | The FDA approved Welireg in combination with Lenvima for advanced clear-cell renal cell carcinoma after prior immunotherapy. |
Why It Matters | The approval provides another treatment option after PD-1 or PD-L1 therapy in a setting where patients may require additional targeted approaches. |
Supporting Context | Belzutifan inhibits HIF-2α while lenvatinib targets multiple receptor tyrosine kinases involved in tumour angiogenesis and growth. |
Key Takeaway | Welireg plus Lenvima is now FDA approved for advanced clear-cell renal cell carcinoma following prior immune-checkpoint therapy. |
What to Watch | Clinical uptake, treatment sequencing and longer-term survival results from LITESPARK-011. |
Primary Source | U.S. Food and Drug Administration |
Relevant Date | 24 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare